This discrepancy is not really shared with other dopamine reuptake inhbitors like bupropion, sibutramine, mazindol or tesofensine, which have very similar or better potencies than copyright as dopamine reuptake inhibitors. These findings have evoked a hypothesis that copyright might also purpose as a so-named "DAT inverse agonist" or "unfavorable a